Financial reports
10-K
2023 FY
Annual report
12 Mar 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
22 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K/A
2021 FY
Annual report (amended)
31 Mar 22
Current reports
8-K
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
8-K
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
12 Mar 24
8-K
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
7 Nov 23
8-K
Regulation FD Disclosure
26 Sep 23
8-K
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
8 Aug 23
8-K
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
28 Jul 23
8-K
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
26 Jul 23
8-K
Other Events
27 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
14 Jun 23
8-K
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
9 May 23
Registration and prospectus
S-8
Registration of securities for employees
12 Mar 24
S-3
Shelf registration
7 Nov 23
424B5
Prospectus supplement for primary offering
28 Jul 23
424B5
Prospectus supplement for primary offering
27 Jul 23
S-8
Registration of securities for employees
22 Mar 23
424B5
Prospectus supplement for primary offering
14 Apr 22
S-8
Registration of securities for employees
15 Mar 22
S-3
Shelf registration
11 Aug 21
S-8
Registration of securities for employees
25 Mar 21
S-8
Registration of securities for employees
28 Jul 20
Other
EFFECT
Notice of effectiveness
16 Nov 23
CORRESP
Correspondence with SEC
13 Nov 23
UPLOAD
Letter from SEC
10 Nov 23
UPLOAD
Letter from SEC
11 Jul 23
CORRESP
Correspondence with SEC
30 Jun 23
UPLOAD
Letter from SEC
27 Jun 23
EFFECT
Notice of effectiveness
24 Aug 21
CORRESP
Correspondence with SEC
19 Aug 21
UPLOAD
Letter from SEC
18 Aug 21
EFFECT
Notice of effectiveness
24 Jul 20
Ownership
4
Douglas A Treco
3 Apr 24
4
Matthew Winton
3 Apr 24
4
Matthew Winton
15 Mar 24
4
Douglas A Treco
15 Mar 24
4
Sanjay Subramanian
15 Mar 24
SC 13D/A
Sofinnova Venture Partners X, L.P.
20 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners II, L.P.
14 Feb 24
SC 13G/A
New Enterprise Associates 15, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24